Skipnavigation

Activartis Logo


Seitenkopf

search

search in Activartis website

Metanavigation / Sprache


Slideshow

  • Slideshow Bild - Topmeldung
    design element

    Start

    Activartis’ proprietary technology platform AV0113 is a completely individualised cancer immune therapy based on dendritic cells.  

  • For the manufacturing of Activartis’ tailored cancer vaccine, a patient’s tumour tissue as well as peripheral blood monocytes are collected.
    design element

    Step 1

    To manufacture Activartis’ tailored cancer vaccine AV0113, both tumour tissue and peripheral blood monocytes are collected from the patient.  

  • Tumour antigens are extracted from the tumour cells; the monocytes are differentiated into dendritic cells.
    design element

    Step 2

    Tumour antigens are extracted from the tumour cells; the monocytes are differentiated in vitro into dendritic cells.  

  • The dendritic cells are charged with the tumour antigens and exposed to lipopolysaccharide and interferon-gamma. This is Activartis’ core process and comprises our intellectual property.
    design element

    Step 3

    The dendritic cells are charged with the tumour antigens and exposed to lipopolysaccharide and interferon-gamma. This process is the core feature of our method and is the intellectual property of Activartis.  

  • Slideshow Bild - Topmeldung
    design element

    Step 4

    The dendritic cells are injected into one of the patient’s inguinal lymph nodes, introducing tumour antigens in order to trigger an anti-tumour immune response.  


Navigation

Servicemenü / Seite drucken



Activartis Biotech GmbH

Activartis is a biotech company based in Vienna and is currently in phase II of a clinical trial to develop a new cancer immunotherapy based on dendritic cells (AV0113). The aim of the phase II trial is to treat an aggressive form of brain tumour. However, it will in principle be able to treat all types of cancerous diseases.

The therapeutic platform combines a completely novel, proprietary approach by utilising a bacterial danger signal in combination with the patient’s tumour antigens together with the proven successful concept of dendritic cells to mobilise the patients’ immune system to combat the disease.

Thomas Felzmann, CEO Activartis


Fußbereich

Zusatznavigation

Inhaltsübersicht